Abstract: The present invention relates to a secretin receptor modulator for use in the prevention and/or treatment of a disease or disorder of energy homeostasis, wherein (a) said secretin receptor modulator is a secretin receptor agonist and said disease or disorder is obesity, dyslipidemia, diabetes, insulin resistance, hyperglycemia, high blood pressure or metabolic syndrome, whereby the secretin receptor agonist increases non-shivering thermogenesis in brown adipocytes and/or increases the expression of uncoupling protein 1 (UCP1) in brown adipocytes and/or decreases food intake in a UCP1-dependent manner resulting in the prevention and/or treatment of said disease or disorder; or (b) said secretin receptor modulator is a secretin receptor antagonist and said disease or disorder is cachexia.

Abstract: The present invention relates to polypeptides for use in treating diseases or disorders of energy homeostasis such as obesity, dyslipidemia, diabetes, insulin resistance, hyperglycemia or the metabolic syndrome. The invention also relates to polynucleotides encoding said polypeptides for use in treating diseases or disorders of energy homeostasis. Also provided by the present invention are pharmaceutical compositions comprising said polypeptides and polynucleotides for use in treating diseases or disorders of energy homeostasis. Said polypeptides, polynucleotides and pharmaceutical compositions may be administered locally, in particular locally into the visceral adipose tissue. Another aspect of the invention relates to a cosmetic product and the use of said cosmetic product for reducing body weight, in particular for reducing abdominal adipose tissue.

Abstract: The present invention relates to polypeptides for use in treating diseases or disorders of energy homeostasis such as obesity, dyslipidemia, diabetes, insulin resistance, hyperglycemia or the metabolic syndrome. The invention also relates to polynucleotides encoding said polypeptides for use in treating diseases or disorders of energy homeostasis. Also provided by the present invention are pharmaceutical compositions comprising said polypeptides and polynucleotides for use in treating diseases or disorders of energy homeostasis. Said polypeptides, polynucleotides and pharmaceutical compositions may be administered locally, in particular locally into the visceral adipose tissue. Another aspect of the invention relates to a cosmetic product and the use of said cosmetic product for reducing body weight, in particular for reducing abdominal adipose tissue.